Clinical Trials
7 trialsNCT00066677 2021-03-05
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT00426127 2017-12-29
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
University of Iowa
Phase 2 Terminated
NCT00833859 2017-10-09
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01754623 2015-08-13
GTX-RT in Borderline Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00159471 2014-05-22
Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
University of Southern California
Phase NA Terminated